cyproterone acetate has been researched along with Cardiovascular Diseases in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (14.29) | 18.7374 |
| 1990's | 5 (23.81) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| El Aridi, L; Feigerlova, E; Gillet, P; Klein, M; Maurier, A; Yelehe, M | 1 |
| Defreyne, J; den Heijer, M; Hovingh, GK; Klaver, M; Nota, NM; Paldino, A; Simsek, S; T'Sjoen, G; Thijs, A; van Velzen, DM | 1 |
| Aksoy, A; Carlioglu, A; Gozukara, I; Kabil Kucur, S; Kamalak, Z; Keskin, H; Uludag, EU | 1 |
| Akcay, A; Bavbek, N; Gumus, II; Karakurt, F; Kargili, A; Koca, C; Kosar, A; Ozbek, M; Selcoki, Y | 1 |
| Ademoğlu, E; Gokkusu, C; Tamer, S; Tata, G | 1 |
| Bernier, J; Billiet, I; Bolla, M; Collette, L; Cutajar, CL; Dubois, JB; Kuten, A; Mirimanoff, RO; Pfeffer, R; Sternberg, C; Storme, G; Torecilla, JL; Van der Kwast, T; Van Tienhoven, G; Warde, P | 1 |
| D'Amico, AV | 1 |
| Atanassova, I; Kalinov, K; Kirilov, G; Nachev, E; Orbetzova, M; Shigarminova, R; Zacharieva, S | 1 |
| Crippa, D; De Leo, V; la Marca, A; Orlandi, R; Petraglia, F; Setacci, C | 1 |
| Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM | 1 |
| Morin-Papunen, LC; Rautio, K; Ruokonen, A; Tapanainen, JS | 1 |
| Alvarez-Blasco, F; Botella-Carretero, JI; Escobar-Morreale, HF; Lasunción, MA; Luque-Ramírez, M; Martínez-Bermejo, E | 1 |
| Bunck, MC; Giltay, EJ; Gooren, LJ | 1 |
| Karlberg, BE; Risberg, B; Varenhorst, E; Wallentin, L; Wranne, B | 1 |
| Bérubé, S; Bissonnette, F; Fugère, P; Lussier-Cacan, S | 1 |
| Klimenchenko, NI; Smetnik, VP; Zatikian, EP | 1 |
| Andersen, LF; Gram, J; Jespersen, J; Skouby, SO | 1 |
| Hermabessière, J | 1 |
| Moffat, LE | 1 |
| de Pauw, M; de Voogt, HJ; Pavone-Macaluso, M; Smith, PH; Suciu, S | 1 |
| Barasolo, E; de Pauw, M; de Voogt, HJ; Lardennois, B; Pavone-Macaluso, M; Sylvester, R; Viggiano, G | 1 |
2 review(s) available for cyproterone acetate and Cardiovascular Diseases
| Article | Year |
|---|---|
Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience.
Topics: Androgen Antagonists; Cardiovascular Diseases; Cyproterone Acetate; Estradiol; Female; Humans; Male; Osteoporosis; Testosterone; Transsexualism | 2008 |
[Cyproterone acetate: cardiovascular tolerance].
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Cyproterone Acetate; Humans; Male; Prostatic Neoplasms; Risk Factors | 1992 |
8 trial(s) available for cyproterone acetate and Cardiovascular Diseases
| Article | Year |
|---|---|
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Canada; Cardiovascular Diseases; Chemotherapy, Adjuvant; Cyproterone Acetate; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Europe; Fractures, Bone; Goserelin; Humans; Israel; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Neoplasm Invasiveness; Neoplasm Staging; Prostatic Neoplasms; Risk Assessment; Russia; Time Factors; Treatment Outcome | 2010 |
Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cardiovascular Diseases; Cholesterol; Cyproterone Acetate; Ethinyl Estradiol; Female; Humans; Hypoglycemic Agents; Metformin; Obesity; Polycystic Ovary Syndrome; Treatment Outcome | 2005 |
Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
Topics: Administration, Oral; Adult; Androgen Antagonists; Androgens; Blood Glucose; Cardiovascular Diseases; Cyproterone Acetate; Drug Combinations; Dyslipidemias; Ethinyl Estradiol; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Metformin; Polycystic Ovary Syndrome; Risk Factors | 2007 |
Metabolic effect of two hormonal preparations in postmenopausal women.
Topics: Angiotensinogen; Blood Coagulation Factors; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Climacteric; Cyproterone Acetate; Energy Metabolism; Estradiol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Gonadal Steroid Hormones; Humans; Medroxyprogesterone Acetate; Middle Aged; Renin; Risk Factors | 1997 |
Effects of hormone replacement therapy on hemostatic cardiovascular risk factors.
Topics: Cardiovascular Diseases; Cyproterone Acetate; Estradiol; Estrogen Replacement Therapy; Factor VII; Female; Fibrinogen; Hemostasis; Humans; Lipoprotein(a); Middle Aged; Placebos; Plasminogen Activator Inhibitor 1; Postmenopause; Risk Factors; Tissue Plasminogen Activator | 1999 |
Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer.
Topics: Androgen Antagonists; Breast; Buserelin; Cardiovascular Diseases; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Goserelin; Humans; Male; Prospective Studies; Prostatic Neoplasms | 1990 |
Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer tria
Topics: Aged; Body Weight; Cardiovascular Diseases; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Estramustine; Europe; Humans; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Nitrogen Mustard Compounds; Prostatic Neoplasms; Random Allocation; Time Factors | 1986 |
Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological
Topics: Aged; Bone Neoplasms; Carcinoma; Cardiovascular Diseases; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Europe; Follow-Up Studies; Humans; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Prostatic Neoplasms; Random Allocation | 1986 |
11 other study(ies) available for cyproterone acetate and Cardiovascular Diseases
| Article | Year |
|---|---|
Adverse effects of gender-affirming hormonal therapy in transgender persons: Assessing reports in the French pharmacovigilance database.
Topics: Cardiovascular Diseases; Cyproterone Acetate; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Pharmacovigilance; Retrospective Studies; Transgender Persons | 2022 |
Cardiometabolic Effects of Testosterone in Transmen and Estrogen Plus Cyproterone Acetate in Transwomen.
Topics: Administration, Oral; Adolescent; Adult; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cyproterone Acetate; Estrogens; Female; Hormone Replacement Therapy; Humans; Male; Prospective Studies; Sex Factors; Sex Reassignment Procedures; Testosterone; Transdermal Patch; Transgender Persons; Triglycerides; Young Adult | 2019 |
How medical treatment affects mean platelet volume as a cardiovascular risk marker in polycystic ovary syndrome?
Topics: Adolescent; Adult; Androgen Antagonists; Biomarkers; Blood Platelets; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Case-Control Studies; Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Leukocyte Count; Mean Platelet Volume; Metformin; Polycystic Ovary Syndrome; Regression Analysis; Treatment Outcome | 2015 |
Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome.
Topics: Adult; Antigens; Carboxypeptidase B2; Cardiovascular Diseases; Case-Control Studies; Contraceptives, Oral, Hormonal; Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; Female; Humans; Models, Biological; Polycystic Ovary Syndrome; Risk Factors; Thrombosis; Up-Regulation; Young Adult | 2008 |
The benefits of hormone replacement therapy on plasma and platelet antioxidant status and fatty acid composition in healthy postmenopausal women.
Topics: Antioxidants; Blood Platelets; Cardiovascular Diseases; Cyproterone Acetate; Estradiol; Fatty Acids; Female; Glutathione Transferase; Hormone Replacement Therapy; Humans; Lipids; Malondialdehyde; Middle Aged; Oxidative Stress; Postmenopause; Superoxide Dismutase | 2010 |
Is long-term androgen suppression right for everyone with locally advanced prostate cancer?
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Chemotherapy, Adjuvant; Cyproterone Acetate; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Fractures, Bone; Goserelin; Humans; Lymphatic Metastasis; Male; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Prostatic Neoplasms; Risk Assessment; Time Factors; Treatment Outcome | 2010 |
Effect of different hormone replacement therapy regimens on circadian blood pressure profile and active renin in postmenopausal women.
Topics: Administration, Cutaneous; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Circadian Rhythm; Cyproterone Acetate; Drug Combinations; Estradiol; Estrogen Replacement Therapy; Female; Heart Rate; Humans; Middle Aged; Postmenopause; Renin; Triglycerides | 2002 |
Effects of estradiol alone or in combination with cyproterone acetate on carotid artery pulsatility index in postmenopausal women.
Topics: Cardiovascular Diseases; Carotid Artery, Internal; Cholesterol, LDL; Cyproterone Acetate; Estradiol; Estrogen Replacement Therapy; Female; Humans; Lipids; Middle Aged; Postmenopause; Pulsatile Flow; Vasodilation | 2003 |
The treatment of polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate; Diabetes Complications; Dopamine Agonists; Ergolines; Female; Finasteride; Flutamide; Follicle Stimulating Hormone; Gonadotropins; Hirsutism; Humans; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Metformin; Mineralocorticoid Receptor Antagonists; Obesity; Ovulation Induction; Polycystic Ovary Syndrome; Risk Factors; Spironolactone; Weight Loss | 2004 |
[Effects of cyproterone acetate on cardiovascular risk factors in patients with carcinoma of the prostate (author's transl)].
Topics: Aged; Antithrombin III; Cardiovascular Diseases; Cyproterone; Cyproterone Acetate; Hemodynamics; Humans; Lipoproteins; Male; Middle Aged; Prostatic Neoplasms; Risk; Water-Electrolyte Balance | 1981 |
[Replacement hormonal therapy: effects on ECG parameters in postmenopausal women].
Topics: Androgen Antagonists; Cardiovascular Diseases; Cyproterone Acetate; Drug Combinations; Drug Therapy, Combination; Electrocardiography; Estradiol; Estrogens, Conjugated (USP); Female; Follow-Up Studies; Hormone Replacement Therapy; Humans; Levonorgestrel; Middle Aged; Postmenopause; Progesterone Congeners | 1998 |